(2009). A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med
(2005). AL: BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast cancer research and treatment
(2008). AL: Predicting features of breast cancer with gene expression patterns. Breast cancer research and treatment
(2010). Altman RB: Independent component analysis: Mining microarray data for fundamental human gene expression modules.
(2008). Bowtell DD: Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res
(2005). Cannistra SA: Unique gene expression profile based on pathologic response in epithelial ovarian cancer.
(2007). Chinnaiyan AM: Integrative molecular concept modeling of prostate cancer progression. Nat Genet
(2001). Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA
(2004). DC: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell
(2007). de Vijver MJ: Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res
(2002). Diagnosis of multiple cancer types by shrunken centroids of gene expression.
(2000). doi:10.1186/1471-2105-12-310 Cite this article as: Li et al.: Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response.
(2007). E: Aldo-keto reductases (AKR) from the AKR1C subfamily catalyze the carbonyl reduction of the novel anticancer drug oracin in man. Toxicology
(2001). E: Independent Component Analysis.
(2005). EM: Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling.
(2005). Emmert-Buck MR, Chuaqui RF: Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res
(2005). Foekens JA: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet
(2006). Ganesan S: X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell
(2010). GC: Analysis of gene expression in prostate cancer epithelial and interstitial stromal cells using laser capture microdissection.
(2004). Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy.
(2006). Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.
(2005). Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res
(2008). Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med
(2009). Gene-expression signatures in breast cancer.
(2006). Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell
(2008). Glutathione peroxidase 3 is a candidate mechanism of anticancer drug resistance of ovarian clear cell adenocarcinoma. Oncol Rep
(2007). High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol
(2006). L: Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
(2006). LD: Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res
(2008). Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res
(2006). Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature
(2006). Perou CM: Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers.
(2005). Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet
(2000). Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer Res
Pusztai L: Effect of training-sample size and classification difficulty on the accuracy of genomic predictors.
Pusztai L: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. JC l i nO n c o l2008,
(2003). Relevance network between chemosensitivity and transcriptome in human hepatoma cells. Mol Cancer Ther
(2002). SH: Gene expression profiling predicts clinical outcome of breast cancer.
(2007). Sotiriou C: Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.
(2006). Sparse Principal Component Analysis.
(2003). Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics
(2007). Symmans WF: Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol
(2003). Symmans WF: Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res
(2005). The elements of statistical learning: data mining, inference and prediction. The Mathematical Intelligencer
(2007). The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell
(1937). The statistical conception of mental factors.
(2004). Tibshirani R: Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol
(2010). Tong W: DNA microarrays are predictive of cancer prognosis: a re-evaluation. Clin Cancer Res
(2010). Wang ZC: Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med
(2006). WL: An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene